biotech / news / / Newsmax
The Supreme Court on Monday rejected appeals from pharmaceutical companies that object to negotiating Medicare drug prices with the federal government.
The Supreme Court declined to hear pharma companies' appeals against Medicare drug price negotiations.
KEY POINTS
- Lower court rulings dismissing drug manufacturers' claims against the negotiation program remain in place.
- Medicare price negotiations currently cover 25 drugs, including Ozempic, Rybelsus, and Wegovy.
- Expanding to a third round, the program will soon cover 40 drugs with lower prices.
- Ending the Medicare drug negotiation program would require congressional action, as no end date is set.
COMPANIES
Summarized by Newsio from Newsmax. How we summarize →